

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36. (cancelled)

37. (currently amended) A recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome ~~of a virus~~, wherein said foreign nucleic acid (a) encodes a protein selected from the groups consisting of: a feline CD28 protein or an immunogenic portion thereof; a feline CD80 protein or an immunogenic portion thereof; a feline CD86 protein or an immunogenic portion thereof; ~~[[or]]~~and a feline CTLA-4 protein or an immunogenic portion thereof; and (b) is expressed when the recombinant virus is introduced into an appropriate host.

38. (previously presented)The recombinant virus of claim 37 which comprises at least two foreign nucleic acids, wherein each is inserted within a non-essential region of the viral genome.

39. (currently amended) The recombinant virus of claim ~~[[38]]~~37 which comprises at least three foreign nucleic acids, wherein each is inserted within a non-essential region of the viral genome.

40. (currently amended) The recombinant virus of claim ~~[[38]]~~37 which comprises four foreign nucleic acids, wherein each is inserted within a non-essential region of the viral genome.

41. (previously presented)The recombinant virus of claim 37, wherein the virus is raccoonpox virus, a swinepox virus, or a feline herpesvirus.

42. (previously presented)The recombinant virus of claim 37 comprising more than one foreign nucleic acid, wherein each foreign nucleic acid is inserted into the same non-essential region of the viral genome.

43. (previously presented)The recombinant virus of claim 37 comprising more than one foreign nucleic acid, wherein each foreign nucleic acid is not inserted into the same non-essential region of the viral genome.

44. (previously presented) The recombinant virus of claim 37 further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen.
45. (previously presented) The recombinant virus of claim 44, wherein the pathogen is a feline pathogen, a rabies virus, Chlamydia, *Toxoplasma gondii*, *Dirofilaria immitis*, a flea, or a bacterial pathogen.
46. (previously presented) The recombinant virus of claim 45, wherein the feline pathogen is feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), feline infectious peritonitis virus (FIP), feline panleukopenia virus, feline calicivirus, feline reovirus type 3, feline rotavirus, feline coronavirus, feline syncytial virus, feline sarcoma virus, feline herpesvirus, feline Borna disease virus, or a feline parasite.
47. (previously presented) The recombinant virus of claim 37, wherein at least one foreign nucleic acid, comprises a promoter for expressing the foreign nucleic acid.
48. (currently amended) The recombinant virus of claim 37, wherein the expression of at least one foreign nucleic acid is under the control of a promoter endogenous to the virus.
49. (previously presented) The recombinant virus of claim 37 further comprising a foreign nucleic acid encoding a detectable marker.
50. (currently amended) The recombinant virus of claim 49, wherein the detectable marker is [[*E. coli*]] *E. coli* beta galactosidase.
51. (previously presented) The recombinant virus of claim 46, wherein the immunogen from a feline pathogen is FIV gag protease, a FIV envelope protein, a FeLV gag protease, or a FeLV envelope protein.
52. (previously presented) The recombinant virus of claim 37, wherein the virus is a feline herpesvirus and the non-essential region is the glycoprotein E gene of feline herpesvirus.
53. (currently amended) The recombinant ~~feline herpesvirus~~ of claim 48, where in the recombinant virus is a feline herpesvirus [[is]] designated S-FHV-031 (ATCC Accession No. VR-2604).

54. (previously presented)The recombinant virus of claim 37, wherein the virus is swinepox virus and the non-essential region is the larger Hind III to Bgl II subfragment of the Hind III M fragment of swinepox virus.

55. (currently amended) The recombinant virus of claim 50, wherein the recombinant virus is a swinepox virus [[is]]designated S-SPV-246 (ATCC Accession No. VR-2603).

56. (previously presented)The recombinant virus of claim 37, wherein the portion of the CD28, CD80, or CD86 protein is the soluble portion of the protein.

57. (previously presented)The recombinant virus of claim 37, where the foreign nucleic acid encodes the feline CTLA-4 protein.

58. (previously presented)A vaccine comprising an effective immunizing amount of the recombinant virus of claim 37 and a suitable carrier.

59. (previously presented)The vaccine of claim 58, wherein the effective immunizing amount of the recombinant virus is an amount between about 1×10^5 pfu/ml and about 1×10^8 pfu/ml.

60. (previously presented)The vaccine of claim 58 which further comprises an admixture of the recombinant virus with an effective immunizing amount of a second immunogen.

61. (previously presented)A method of enhancing an immune response in a feline which comprises administering to the feline an effective immunizing amount of the recombinant virus of claim 37.

62. (previously presented)A method for immunizing a feline which comprises administering to the feline an effective immunizing amount of the recombinant virus of claim 37.

63. (previously presented)A method for suppressing an immune response in a feline which comprises administering to the feline any effective suppressing amount of the recombinant virus of claim 56.

64. (previously presented)The method of claim 61, wherein the administering comprises intravenous, subcutaneous, intramuscular, transmuscular, topical, oral, or intraperitoneal administration.

65. (previously presented) The method of claim 63, wherein the feline is the recipient of a transplanted organ or tissue or is suffering from an immune response.
66. (cancelled)
67. (currently amended) A method for reducing or abrogating a tumor in a feline which comprises administering to the tumor in the feline a recombinant virus of claim 37, wherein the nucleic acid encodes a feline CD80 protein, a feline CD86 protein or a combination thereof in an amount effective to reduce or abrogate the tumor.
68. (previously presented) The method of claim 67, wherein the recombinant virus further comprises, and is capable of expressing, a feline tumor associated antigen and the administration is effected systemically.
69. (previously presented) The recombinant virus of claim 37, further comprising a nucleic acid encoding feline immunodeficiency virus genome or a portion thereof.
70. (previously presented) The recombinant virus of claim 37, further comprising a nucleic acid encoding feline leukemia virus genome or a portion thereof.
71. (previously presented) The recombinant virus of claim 69, further comprising a nucleic acid encoding feline GM-CSF or feline IL-12 p35 and p40.
72. (previously presented) The recombinant virus of claim 70, further comprising a nucleic acid encoding feline GM-CSF or feline IL-12 p35 and p40.
75. (previously presented) The recombinant virus of claim 37, further comprising a nucleic acid encoding the feline infectious peritonitis virus genome or a portion thereof.
76. (previously presented) The recombinant virus of claim 37, wherein the virus is a swinepox virus and the nonessential region is within the HindIII K fragment.
77. (previously presented) The recombinant virus of claim 37, wherein the virus is a swinepox virus and the nonessential region is within the HindIII N fragment.